• Mutation; HGNC; HGNC:583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Homozygous (from parent cell line).
  
• Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line).
  
• Mutation; HGNC; HGNC:2514; CTNNB1; Simple; p.Asn287Ser (c.860A>G); ClinVar=VCV000133954; Zygosity=Homozygous (from parent cell line).
  
• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Tyr103fs*37 (c.308_321delTGTGTAACAGTTCC); Zygosity=Homozygous (from parent cell line).
  

PubMed=21447798; DOI=10.1126/scisignal.2001752
Little A.S., Balmanno K., Sale M.J., Newman S., Dry J.R., Hampson M., Edwards P.A.W., Smith P.D., Cook S.J.
Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells.
Sci. Signal. 4:Ra17.1-Ra17.15(2011)

PubMed=31048689; DOI=10.1038/s41467-019-09438-w; PMCID=PMC6497655
Sale M.J., Balmanno K., Saxena J., Ozono E., Wojdyla K., McIntyre R.E., Gilley R., Woroniuk A., Howarth K.D., Hughes G., Dry J.R., Arends M.J., Caro P., Oxley D., Ashton S., Adams D.J., Saez-Rodriguez J., Smith P.D., Cook S.J.
MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAF(V600E) amplification whereas KRAS(G13D) amplification promotes EMT-chemoresistance.
Nat. Commun. 10:2030.1-2030.22(2019)